Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPILEPSIE database Resource Report Resource Website 1+ mentions |
EPILEPSIE database (RRID:SCR_003179) | data or information resource, database | A comprehensive database for human surface and intracranial EEG data that is suitable for a broad range of applications e.g. of time series analyses of brain activity. Currently, the EU database contains annotated EEG datasets from more than 200 patients with epilepsy, 50 of them with intracranial recordings with up to 122 channels. Each dataset provides EEG data for a continuous recording time of at least 96 hours (4 days) at a sample rate of up to 2500 Hz. Clinical patient information and MR imaging data supplement the EEG data. The total duration of EEG recordings included execeeds 30000 hours. The database is composed of different modalities: Binary files with EEG recording / MR imaging data and Relational database for supplementary meta data. | seizure, electroencephalography, mri, eeg recording, metadata, intracranial, surface, time series analyses, brain activity, brain, clinical, image collection |
is listed by: NeuroImaging Tools and Resources Collaboratory (NITRC) has parent organization: University of Freiburg; Baden-Wurttemberg; Germany |
Epilepsy | Excellence Initiative of the German Federal and State Governments ; European Union 211713; BMBF 01GQ0420; German Science Foundation Ti 315/4-2 |
PMID:22738131 | Free, Freely available | nlx_156892 | http://www.nitrc.org/projects/epilepsiaedb http://epilepsy-database.eu/project/ http://www.epilepsiae.eu http://epilepsy-database.eu | SCR_003179 | EPILEPSIAE Project Database, European Epilepsy Database | 2026-02-14 02:06:11 | 3 | ||||
|
Protochlamydia amoebophila UWE25 Resource Report Resource Website |
Protochlamydia amoebophila UWE25 (RRID:SCR_008222) | data or information resource, database | THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 15, 2013. This is the official database of the environmental chlamydia genome project. This resource provides access to finished sequence for Parachlamydia-related symbiont UWE25 and to a wide range of manual annotations, automatical analyses and derived datasets. Functional classification and description has been manually annotated according to the Annotation guidelines. Chlamydiae are the major cause of preventable blindness and sexually transmitted disease. Genome analysis of a chlamydia-related symbiont of free-living amoebae revealed that it is twice as large as any of the pathogenic chlamydiae and had few signs of recent lateral gene acquisition. We showed that about 700 million years ago the last common ancestor of pathogenic and symbiotic chlamydiae was already adapted to intracellular survival in early eukaryotes and contained many virulence factors found in modern pathogenic chlamydiae, including a type III secretion system. Ancient chlamydiae appear to be the originators of mechanisms for the exploitation of eukaryotic cells. Environmental chlamydiae have recently been recognized as obligate endosymbionts of free-living amoebae and have been implicated as potential human pathogens. Environmental chlamydiae form a deep branching evolutionary lineage within the medically important order Chlamydiales. Despite their high diversity and ubiquitous distribution in clinical and environmental samples only limited information about genetics and ecology of these microorganisms is available. The Parachlamydia-related Acanthamoeba symbiont UWE25 was therefore selected as representative environmental chlamydia strain for whole genome sequencing. Comparative genome analysis was performed using PEDANT and simap. Sponsors: The environmental chlamydia genome project was funded by the bmb+f (German Federal Ministry of Education and Research) and is part of the Competence Network PathoGenoMiK. | ecology, endosymbiont, environmental, eukaryote, eukaryotic, evolutionary, functional, gene, genetic, acanthamoeba, amoebae, blindness, cell, chlamydia, classification, clinical, genome, human, intracellular, lateral, lineage, mechanism, microorganism, obligate, parachlamydia, pathogen, pathogenic, sequence, sexually, strain, survival, symbiont, transmitted disease, uwe25, virulence | THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-21310 | SCR_008222 | Protochlamydia amoebophila UWE25 | 2026-02-14 02:06:34 | 0 | |||||||||
|
National Cancer Institute 3D Structure Database Resource Report Resource Website |
National Cancer Institute 3D Structure Database (RRID:SCR_008211) | data or information resource, database | The NCI DIS 3D database is a collection of 3D structures for over 400,000 drugs. The database is an extension of the NCI Drug Information System. The structural information stored in the DIS is only the connection table for each drug. The connection table is just a list of which atoms are connected and how they are connected. It is essentially a searcheable database of three-dimensional structures has been developed from the chemistry database of the NCI Drug Information System (DIS), a file of about 450,000 primarily organic compounds which have been tested by NCI for anticancer activity. The DIS database is very similar in size and content to the proprietary databases used in the pharmaceutical industry; its development began in the 1950s; and this history led to a number of problems in the generation of 3D structures. This information can be searched to find drugs that share similar patterns of connections, which can correlate with similar biological activity. But the cellular targets for drug action, as well as the drugs themselves, are 3 dimensional objects and advances in computer hardware and software have reached the point where they can be represented as such. In many cases the important points of interaction between a drug and its target can be represented by a 3D arrangement of a small number of atoms. Such a group of atoms is called a pharmacophore. The pharmacophore can be used to search 3D databases and drugs that match the pharmacophore could have similar biological activity, but have very different patterns of atomic connections. Having a diverse set of lead compounds increases the chances of finding an active compound with acceptable properties for clinical development. Sponsor: The ICBG are supported by the Cooperative Agreement mechanism, with funds from nine components of the NIH, the National Science Foundation, and the Foreign Agricultural Service of the USDA. | drug, 3d, 3d molecular structures, anticancer, atom, atomic, biological, cellular, chemistry, clinical, compound, development, interaction, lead, organic, pattern, pharmaceutical, pharmacophore, structural, structure |
has parent organization: National Cancer Institute has parent organization: National Cancer Institute |
nif-0000-21279 | SCR_008211 | NCI DIS 3D Database | 2026-02-14 02:06:42 | 0 | |||||||||
|
Layton Center Clinical Data Resources Resource Report Resource Website |
Layton Center Clinical Data Resources (RRID:SCR_008822) | data or information resource, database | A database housing longitudinal relational research data from over 4,000 research subjects. The database includes the following types of data: physical and neurological exam findings, neurocognitive test scores, personal and family history of dementia, personal demographic genotypes (APOE, HLA), age at service evaluations, age at onset, age at death, clinical diagnosis, neuropathology diagnosis, tissue inventory information (when available), health status, medications, laboratory tests, and MRI data. | clinical data, alzheimer's disease, dementia, genotype, late adult human, longitudinal, clinical, mri |
is related to: Oregon Brain Bank has parent organization: OHSU Layton Aging and Alzheimer's Disease Center |
Aging, Alzheimer's disease | Researchers must submit a request | nlx_144446 | SCR_008822 | Layton Aging and Alzheimer's Disease Center Clinical Data Resources | 2026-02-14 02:06:36 | 0 | |||||||
|
Vaccine damage reports database Resource Report Resource Website |
Vaccine damage reports database (RRID:SCR_010740) | Vaccine damage reports database | data or information resource, database | Database of case reports of adverse reactions to vaccinations. There are 806 reports (May 2013). If you would like to report a case, please go to report your own vaccine reaction. The user may search by keywords or sort by vaccine, country, age, outcome, gender and hospital admission. | vaccine, adverse reaction, clinical, male, female, child, adult | Adverse reaction to vaccine, Aging | The community can contribute to this resource | nlx_97470 | SCR_010740 | Vaccine damages database, Adverse reaction/vaccine damage database | 2026-02-14 02:06:39 | 0 | |||||||
|
CERAD - Consortium to Establish a Registry for Alzheimer's Disease Resource Report Resource Website 1000+ mentions |
CERAD - Consortium to Establish a Registry for Alzheimer's Disease (RRID:SCR_003016) | CERAD | material resource, assessment test provider | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 4, 2023.Consortium that developed brief, standardized and reliable procedures for the evaluation and diagnosis of patients with Alzheimer's disease (AD) and other dementias of the elderly. These procedures included data forms, flipbooks, guidebooks, brochures, instruction manuals and demonstration tapes, which are now available for purchase. The CERAD assessment material can be used for research purposes as well as for patient care. CERAD has developed several basic standardized instruments, each consisting of brief forms designed to gather data on normal persons as well as on cognitively impaired or behaviorally disturbed individuals. Such data permit the identification of dementia based on clinical, neuropsychological, behavioral or neuropathological criteria. Staff at participating CERAD sites were trained and certified to administer the assessment instruments and to evaluate the subjects enrolled in the study. Cases and controls were evaluated at entry and annually thereafter including (when possible) autopsy examination of the brain to track the natural progression of AD and to obtain neuropathological confirmation of the clinical diagnosis. The CERAD database has become a major resource for research in Alzheimer's disease. It contains longitudinal data for periods as long as seven years on the natural progression of the disorder as well as information on clinical and neuropsychological changes and neuropathological manifestations., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | clinical, behavior, late adult human, male, female, caucasian, african-american, autopsy, longitudinal, neuropsychology, neuropathology, FASEB list | has parent organization: Duke University; North Carolina; USA | Aging, Alzheimer's disease, Dementia, Cognitive impairment, Neurodegenerative disorder, Systemic illness, Cerebrovascular disease, Parkinson's disease, Depressive Disorder | NIA | THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-00523 | SCR_003016 | Consortium to Establish a Registry for Alzheimer's Disease | 2026-02-14 02:06:33 | 2336 | |||||
|
TCMGeneDIT Resource Report Resource Website 10+ mentions |
TCMGeneDIT (RRID:SCR_013396) | data or information resource, database | TCMGeneDIT is a database system providing association information about traditional Chinese medicines (TCMs), genes, diseases, TCM effects and TCM ingredients automatically mined from vast amount of biomedical literature. Integrated protein-protein interaction and biological pathways information collected from public databases are also available. In addition, the transitive relationships among genes, TCMs and diseases could be inferred through the shared intermediates. Furthermore, TCMGeneDIT is useful in deducing possible synergistic or antagonistic contributions of the prescription components to the overall therapeutic effects. TCMGeneDIT is a unique database of various association information about TCMs. The database integrating TCMs with life sciences and biomedical studies would facilitate the modern clinical research and the understanding of therapeutic mechanisms of TCMs and gene regulations. | drug, gene, antagonistic, biomedical, clinical, disease, ingredient, interaction, life science, literature, medicine, pathway, prescription, protein, regulation, research, synergistic, therapeutic | has parent organization: National Taiwan University; Taipei; Taiwan | National Science Council Taiwan ; NTU Frontier and Innovative Research Projects NTUPFIR-96R0107 |
PMID:18854039 | nif-0000-32868 | SCR_013396 | 2026-02-14 02:06:43 | 12 | ||||||||
|
ClinGen Resource Report Resource Website 500+ mentions |
ClinGen (RRID:SCR_014968) | CGR | data or information resource, database | Genomics knowledgebase for clinical relevance of genes and variants for use in research. ClinGen's primary function is to store and share information for the benefit of the scientific community. Laboratory scientists, clinicians, and patients can share and access data. | database, knowledgebase, genomics, healthcare, clinical, FASEB list | Eunice Kennedy Schriver NICHD ; NHGRI U41 HG006834-01A1; NHGRI U01 HG007437-01; NHGRI U01 HG007436-01; NCI HHSN261200800001E; NCI contract HHSN261200800001E |
PMID:26014595 | Free, Available to the scientific community | SCR_014968 | Clinical Genome Resource (ClinGen), Clinical Genome Resource | 2026-02-14 02:06:22 | 898 | |||||||
|
Structured Clinical Interview for DSM-IV Resource Report Resource Website 1+ mentions |
Structured Clinical Interview for DSM-IV (RRID:SCR_003682) | SCID, SCID-I, SCID-II | material resource, assessment test provider | A diagnostic exam used to determine DSM-IV Axis I disorders (SCID-I) (major mental disorders) and Axis II disorders (SCID-II) (personality disorders). An Axis I SCID assessment with a psychiatric patient usually takes between 1 and 2 hours, depending on the complexity of the subject's psychiatric history and their ability to clearly describe episodes of current and past symptoms. A SCID with a non-psychiatric patient takes 1/2 hour to 1-1/2 hours. A SCID-II personality assessment takes about 1/2 to 1 hour. The instrument was designed to be administered by a clinician or trained mental health professional. (Adapter from Wikipedia) | clinical, mental health, semi-structured interview, interview | Mental disease, Personality disorder | Acknowledgement requested, Commercial license | nlx_157838 | SCR_003682 | 2026-02-14 02:07:04 | 8 | ||||||||
|
ECNP Resource Report Resource Website 1+ mentions |
ECNP (RRID:SCR_000501) | ECNP | data or information resource, community building portal, portal | A pan-European scientific association to encourage research across the neurosciences and to translate new knowledge on fundamental disease mechanisms into new medicines and clinical applications. As an interdisciplinary forum for the science and treatment of disorders of the brain, they promote the communication and cross- fertilization of high-quality experimental and clinical research across the field of neuroscience. ECNP is a non-profit member-based association, independently governed and self-funded. ECNP is a public-interest-serving entity. | brain, neuroscience, disease mechanism, medicine, clinical, disease | is parent organization of: Preclinical Data Forum Network | Brain disorder | nlx_158605 | SCR_000501 | European College of Neuropsychopharmacology, ECNP - neuroscience applied | 2026-02-15 09:17:56 | 1 | |||||||
|
LONI Image and Data Archive Resource Report Resource Website 50+ mentions |
LONI Image and Data Archive (RRID:SCR_007283) | IDA, LONI IDA, | image collection, data or information resource, database | Archive used for archiving, searching, sharing, tracking and disseminating neuroimaging and related clinical data. IDA is utilized for dozens of neuroimaging research projects across North America and Europe and accommodates MRI, PET, MRA, DTI and other imaging modalities. | data storage, mri, pet, mra, dti, neuroimaging, image storage, histology, fmri, spect, normal, control, alzheimer's disease, mild cognitive impairment, data sharing, clinical, protection, brain, cryosection, FASEB list |
is recommended by: National Library of Medicine is listed by: NIH Data Sharing Repositories |
Control, Autism, Parkinson's disease, Alzheimer's disease, Mild Cognitive Impairment, Normal control, Aging | NIBIB | Restricted | nif-0000-00040, r3d100012840 | https://ida.loni.usc.edu/login.jsp?search=true https://doi.org/10.17616/R39N6D |
https://ida.loni.ucla.edu/login.jsp | SCR_007283 | , IDA, LONI Database, LONI, Image Data Archive | 2026-02-15 09:19:23 | 87 | |||
|
National Center for Image-Guided Therapy Resource Report Resource Website 1+ mentions |
National Center for Image-Guided Therapy (RRID:SCR_001419) | NCIGT | biomedical technology research center, training resource | Biomedical Technology Resource Center that serves as a national resource for all aspects of research into medical procedures that are enhanced by imaging. Its common goal is to provide more effective patient care. The center is focused on the multidisciplinary development of innovative image-guided intervention technologies to enable effective, less invasive clinical treatments that are not only more economical, but also produce better results for patients. The NCIGT is helping to implement this vision by serving as a proving ground for some of the next generation of medical therapies. | clinical, patient care, imaging, medical procedure | has parent organization: Harvard Medical School; Massachusetts; USA | NIBIB P41EB015898 | Free, Freely Available | nlx_152641 | SCR_001419 | National Center for Image Guided Therapy | 2026-02-14 02:07:18 | 2 | ||||||
|
Family Investigation of Nephropathy of Diabetes Resource Report Resource Website |
Family Investigation of Nephropathy of Diabetes (RRID:SCR_001525) | FIND, F.I.N.D. | clinical trial, resource | Multicenter observational study designed to identify genetic determinants of diabetic nephropathy. It is conducted in eleven U.S. clinical centers and a coordinating center, and with four ethnic groups (European Americans, African Americans, Mexican Americans, and American Indians). Two strategies are used to localize susceptibility genes: a family-based linkage study and a case-control study using mapping by admixture linkage disequilibrium (MALD). In the family-based study, probands with diabetic nephropathy are recruited with their parents and selected siblings. Linkage analyses will be conducted to identify chromosomal regions containing genes that influence the development of diabetic nephropathy or related quantitative traits such as serum creatinine concentration, urinary albumin excretion, and plasma glucose concentrations. Regions showing evidence of linkage will be examined further with both genetic linkage and association studies to identify genes that influence diabetic nephropathy or related traits. Two types of MALD studies are being done. One is a case-control study of unrelated individuals of Mexican American heritage in which both cases and controls have diabetes, but only the case has nephropathy. The other is a case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring are genotyped when available to provide haplotype data. The specific goals of this program: * Delineate genomic regions associated with the development and progression of renal disease(s) * Evaluate whether there is a genetic link between diabetic nephropathy and diabetic retinopathy * Improve outcomes * Provide protection for people at risk and slow the progression of renal disease * Help establish a resource for genetic studies of kidney disease and diabetic complications by creating a repository of genetic samples and a database * Encourage studies of the genetics of progressive renal disease | genetic susceptibility, genetic pathway, renal, kidney, outcome, gene, genetics, european-american, african-american, mexican-american, american-indian, linkage association study, admixture linkage disequilibrium, mapping by admixture linkage disequilibrium, serum creatinine, urinary protein excretion, plasma glucose level, blood pressure, blood lipid level, trait, linkage, adult human, male, female, clinical |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
NIDDK 5R01DK053591 | PMID:15642484 | Free, Freely available | nlx_152825 | https://www.niddkrepository.org/studies/find/ | SCR_001525 | Family Investigation of Nephropathy and Diabetes (F.I.N.D.), Family Investigation of Nephropathy & Diabetes | 2026-02-14 02:07:49 | 0 | ||||
|
Clinical Islet Transplantation Study Resource Report Resource Website 1+ mentions |
Clinical Islet Transplantation Study (RRID:SCR_001515) | CIT Study | clinical trial, resource | Network of centers to conduct studies of islet transplantation in patients with type 1 diabetes to improve the safety and long-term success of methods for transplanting islets. It is the aim of this trial to improve methods of isolating islets, to improve techniques for the administering those transplanted islets; and to develop approaches to minimize the toxic effects of immunosuppressive drugs required for transplantation. | islet transplantation, islet, insulin, beta cell, pancreas, autoimmune, clinical | is listed by: NIDDK Information Network (dkNET) | Type 1 diabetes, Diabetes | NIDDK U01DK070431 | Free, Freely available | nlx_152840 | SCR_001515 | Clinical Islet Transplantation Trial, Islet Transplantation Trials for Type 1 Diabetes | 2026-02-14 02:07:27 | 4 | |||||
|
Center for In Vivo Microscopy Resource Report Resource Website 10+ mentions |
Center for In Vivo Microscopy (RRID:SCR_001426) | CIVM | biomedical technology research center, training resource | Biomedical technology research center dedicated to the development of novel imaging methods for the basic scientist and the application of the methods to important biomedical questions. The CIVM has played a major role in the development of magnetic resonance microscopy with specialized MR imaging systems capable of imaging at more than 500,000x higher resolution than is common in the clinical domain. The CIVM was the first to demonstrate MR images using hyperpolarized 3He which has been moved from mouse to man with recent clinical trials performed at Duke in collaboration with GE. More recently the CIVM has developed the molecular imaging workbench---a system dedicated to multimodality cardiopulmonary imaging in the rodent. Their collaborators are employing these unique imaging systems in an extraordinary range of mouse and rat models of neurologic disease, cardiopulmonary disease and cancer to illuminate the underlying biology and explore new therapies. | imaging, magnetic resonance microscopy, magnetic resonance imaging, clinical, mri, ct, x-ray, ultrasound, confocal, optical, spect | has parent organization: Duke University; North Carolina; USA | Cardiopulmonary disease, Cancer, Neurological disease | NIBIB 4P41EB015897-27 | Free, Freely Available | nlx_152650 | SCR_001426 | Duke Center for In Vivo Microscopy | 2026-02-14 02:07:18 | 10 | |||||
|
RiVuR Resource Report Resource Website 1+ mentions |
RiVuR (RRID:SCR_001539) | RIVUR | clinical trial, resource | Multicenter, randomized, double-blind, placebo-controlled trial is designed to determine whether daily antimicrobial prophylaxis is superior to placebo in preventing recurrence of urinary tract infection (UTI) in children with vesicoureteral reflux (VUR). The basic eligibility criteria are: (1) age at randomization of at least 2 months, but less than 6 years, (2) a diagnosed first febrile or symptomatic UTI within 42 days prior to randomization that was appropriately treated, and (3) presence of Grade I-IV VUR based on voiding cystourethrogram (VCUG). Patients will be randomly assigned to treatment for 2 years with daily antimicrobial prophylaxis (trimethoprim-sulfamethoxazole) or placebo. The study is designed to recruit 600 children (approximately 300 in each treatment group) over an 18-24 month period. The primary endpoint is recurrence of UTI. In addition, patients will be evaluated for secondary endpoints related to renal scarring and antimicrobial resistance. Scarring will be determined based on renal scintigraphy by 99mTc dimercaptosuccinic (DMSA) scan. Quality of life, compliance, safety parameters, utilization of health resources, and change in VUR will be assessed periodically throughout the study. | child, antimicrobial prophylaxis, placebo, antibiotic, renal scarring, pediatric, trimethoprim-sulfamethoxazole, intervention, kidney, antibiotic resistance, young human, infant, bibliography, clinical, trimethoprim, sulfamethoxazole |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Vesico-ureteral reflux, Urinary tract infection | NIDDK | PMID:19570724 PMID:19018048 PMID:18076937 PMID:19018047 PMID:19086141 |
Free, Freely available | nlx_152848 | http://www.cscc.unc.edu/rivur/ | SCR_001539 | Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR), Randomized Intervention for Children with Vesicoureteral Reflux, Randomized Intervention for Vesicoureteral Reflux | 2026-02-14 02:07:49 | 1 | |||
|
Type 1 Diabetes Preclinical Testing Program Resource Report Resource Website |
Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) | T1D-PTP, NIDDKT1D-PTP | service resource, resource | THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation. | testing, therapeutic, clinical, drug, preclinical, therapy, drug development, high-throughput screening, animal model, formulation, pharmacology, toxicology |
is related to: Type 1 Diabetes - Rapid Access to Intervention Development is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152741 | SCR_006861 | Type 1 Diabetes Preclinical Testing Program (T1D-PtP), NIDDKType 1 Diabetes Preclinical Testing Program | 2026-02-14 02:07:53 | 0 | |||||
|
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit Resource Report Resource Website |
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit (RRID:SCR_006806) | GLND | clinical trial, resource | Multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care unit (SICU) care and parenteral nutrition (PN) after cardiac, vascular, or intestinal surgery. Patients who required PN and SICU care will receive either standard glutamine (GLN)-free PN (STD-PN) or isocaloric, isonitrogenous alanyl-glutamine dipeptide (AG)-PN until enteral feedings are established. The study will determine whether AG-PN decreases hospital mortality, nosocomial infection and other important indices of morbidity and will obtain mechanistically relevant observational data in the subjects on whether AG-PN a) increases serial blood concentrations of glutathione (GSH), heat shock proteins (HSP)-70 and -27, and glutamine; b) decreases the serum presence of the bacterial products flagellin and lipopolysaccharide (LPS) and the adaptive immune response to these mediators; and c) improves key indices of innate and adaptive immunity. | parenteral nutrition, glutamine, glutamine dipeptide, clinical, outcome, adult human, mortality, nosocomial infection, immune cell function, hospital morbidity, morbidity, intensive care |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Emory University; Georgia; USA |
Critical illness | NIDDK U01DK069322 | PMID:18596310 | nlx_152823 | http://www.sph.emory.edu/GLND | SCR_006806 | Phase III Study on the Efficacy of Glutamine Dipeptide-Supplemented Parenteral Nutrition in Surgical ICU Patients, Efficacy and Mechanisms of GLN Dipeptide in the SICU, Efficacy and Mechanisms of GLN Dipeptide in the SICU (GLND), GLND trial | 2026-02-14 02:07:23 | 0 | ||||
|
ACCORD Resource Report Resource Website 100+ mentions |
ACCORD (RRID:SCR_009015) | ACCORD | clinical trial, resource | Study testing whether strict glucose control lowers the risk of heart disease and stroke in adults with type 2 diabetes. In addition the study is exploring: 1) Whether in the context of good glycemic control the use of different lowering lipid drugs will further improve these outcomes and 2) If strict control of blood pressure will also have additional beneficial effects on reducing cardiovascular disease. The design was a randomized, multicenter, double 2 X 2 factorial trial in 10,251 patients with type 2 diabetes mellitus. It was designed to test the effects on major CVD events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides (in the context of good LDL-C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control), each compared to an appropriate control. All 10,251 participants were in an overarching glycemia trial. In addition, one 2 X 2 trial addressed the lipid question in 5,518 of the participants and the other 2 X 2 trial addressed the blood pressure question in 4,733 of the participants. The glycemia trial was terminated early due to higher mortality in the intensive compared with the standard glycemia treatment strategies. The results were published in June 2008 (N Eng J Med 2008;358:2545-59). Study-delivered treatment for all ACCORD participants was stopped on June 30, 2009, and the participants were assisted as needed in transferring their care to a personal physician. The lipid and blood pressure results (as well as the microvascular outcomes and eye substudy results) were published in 2010. All participants are continuing to be followed in a non-treatment observational study. | middle adult human, late adult human, glycemic control, lowering lipid drug, blood pressure, lipid, clinical |
is related to: NIDDK Information Network (dkNET) has parent organization: National Heart Lung and Blood Institute |
Cardiovascular disease, Stroke, Type 2 diabetes, Diabetes, Aging | NHLBI ; NIDDK ; NEI ; CDC ; NIA |
PMID:23490598 PMID:23253271 PMID:23238658 PMID:22723583 PMID:22646230 |
nlx_152746 | SCR_009015 | Action to Control Cardiovascular Disease Risk in Diabetes | 2026-02-14 02:07:33 | 173 | |||||
|
Italian Rett Syndrome database Resource Report Resource Website 1+ mentions |
Italian Rett Syndrome database (RRID:SCR_002000) | Rett syndrome bank | material resource, biomaterial supply resource | Data and biospecimen from Rett Syndrome patients shared with the scientific community with the ability to visualize the list of available samples and select those with specific clinical and molecular features. It also contains information on biospecimen samples from x-linked retardation, microdeletion, duplication syndromes, autosomal MR, and retinoblastoma. The bank is active since 1998 and it is located in the Medical Genetics Unit, at the University Hospital of Siena. The bank is divided in three distinct sections: # Rett Syndrome. This section contains samples from patients affected by Rett syndrome, a neurodegenerative disease affecting almost exclusively girls with an estimated frequency of 1:10000-15000 live born. By accessing the section users can see a list of all patients available with their phenotype, the specific MECP2 or CDKL5 mutation if known and the kind of biological samples available for each patient. The availability of this large panel of patients is potentially important for the clarification of the molecular bases of Rett syndrome. In fact, a 20-30 of Rett cases do not have MECP2 or CDKL5 mutations. These patients might bear intronic/promoter MECP2 or CDKL5 mutations or they might have alterations in one or more genes different from MECP2 or CDKL5, as suggested by the identification of various chromosomal rearrangements. To confirm a causative role of these rearrangements, and to identify the relevant gene/s, it is important to collect a great number of patients in which to search for overlapping rearrangements or point mutations in candidate genes. # X-Linked Mental Retardation. This section contains samples collected by the centers belonging to the Italian network on X-linked mental retardation, which includes the laboratory of bank curators (for specific information on the network goals and organization, go to the section page). Mental retardation (MR) is the most frequent cause of serious handicap in humans with an estimated prevalence of 0,3-0,5 for moderate to severe MR (IQ<50) which increases to 1-1,5 when mild MR (IQ 50-70) is included. It is calculated that about 20-25 of mentally retarded males have a mutation in a gene on the X chromosome (X-linked mental retardation). X-linked mental retardation is a genetically heterogeneous condition. This is particularly true for the non-syndromic form (MRX), where MR is the only consistent clinical finding and no distinctive features between patients exist. In this situation the only possibility to group patients from different families is represented by linkage analysis, which needs the availability of large families. However, families linked to the same region demonstrate different causative genes. In these conditions, the number of patients available for analysis is a discriminating factor since a large number of patients need to be tested in order to fully confirm or exclude the involvement of a gene in MRX. # Other. This section of the bank contains biological materials and clinical data of patients with other genetic disorders (different from Rett and X-linked mental retardation). Part of this section is dedicated to Alport syndrome. Services: * Isolation of leukocytes from human peripheral blood samples * Establishment of EBV transformed lymphoblastoid cell lines from human peripheral blood leukocytes. * DNA extraction. * Plasma isolation. * Storage: ** Cryo-preservation of transformed cell lines and primary leukocytes at 135��C ** Storage of DNA at 20 degrees C ** Storage of plasma at 20 degrees C * Distribution of the stored biological samples. | duplication syndrome, autosomal mr, microdeletion, retinoblastoma, mecp2, cdkl5, foxg1, clinical, mutation, phenotype, lymphoblastoid cell line, leukocyte, dna, plasma, blood, biomaterial manufacture |
is listed by: One Mind Biospecimen Bank Listing has parent organization: University of Siena; Tuscany; Italy |
Rett Syndrome, Duplication syndrome, Autosomal MR, Microdeletion, Retinoblastoma, X-linked retardation | Telethon Foundation | THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-12492 | http://www.biobank.unisi.it/ScegliArchivio.asp | SCR_002000 | 2026-02-15 09:18:13 | 1 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the Neuroscience Information Framework Project, designed to serve the biomedical research community. NIF maintains the largest searchable collection of neuroscience data, the largest catalog of biomedical resources, and the largest ontology for neuroscience on the web. We welcome all feedback and suggestions and are actively looking for resource providers to make their resources accessible through NIF. Learn about the tools available to help you share your data and discover a dynamic inventory of Web-based neuroscience resources.
